See more : Cadence Design Systems, Inc. (CDNS) Income Statement Analysis – Financial Results
Complete financial analysis of Haemonetics Corporation (HAE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Haemonetics Corporation, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Toyota Industries Corporation (TYIDF) Income Statement Analysis – Financial Results
- Korea Electric Power Industrial Development Co., Ltd (130660.KS) Income Statement Analysis – Financial Results
- Highlander Silver Corp. (LDOMF) Income Statement Analysis – Financial Results
- zSpace, Inc. Common stock (ZSPC) Income Statement Analysis – Financial Results
- Monopar Therapeutics Inc. (MNPR) Income Statement Analysis – Financial Results
Haemonetics Corporation (HAE)
About Haemonetics Corporation
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.31B | 1.17B | 993.20M | 870.46M | 988.48M | 967.58M | 903.92M | 886.12M | 909.68M | 910.37M | 938.51M | 891.99M | 727.84M | 676.69M | 645.43M | 597.88M | 516.44M | 449.61M | 419.73M | 383.60M | 364.23M | 336.96M | 319.97M | 293.86M | 277.92M | 282.10M | 285.80M | 309.80M | 278.20M | 262.40M | 248.40M | 216.30M | 176.40M | 157.30M |
| Cost of Revenue | 617.51M | 553.56M | 487.69M | 472.63M | 503.97M | 550.04M | 492.02M | 507.62M | 503.80M | 475.96M | 470.14M | 463.86M | 358.60M | 321.49M | 307.95M | 289.71M | 258.72M | 222.31M | 199.20M | 185.72M | 192.11M | 182.26M | 165.14M | 126.95M | 121.70M | 124.00M | 127.10M | 137.80M | 110.50M | 103.90M | 94.20M | 88.80M | 78.50M | 0.00 |
| Gross Profit | 691.55M | 615.10M | 505.50M | 397.84M | 484.51M | 417.54M | 411.91M | 378.49M | 405.87M | 434.42M | 468.37M | 428.13M | 369.24M | 355.21M | 337.48M | 308.17M | 257.73M | 227.30M | 220.54M | 197.88M | 172.12M | 154.70M | 154.83M | 166.91M | 156.22M | 158.10M | 158.70M | 172.00M | 167.70M | 158.50M | 154.20M | 127.50M | 97.90M | 157.30M |
| Gross Profit Ratio | 52.83% | 52.63% | 50.90% | 45.70% | 49.02% | 43.15% | 45.57% | 42.71% | 44.62% | 47.72% | 49.91% | 48.00% | 50.73% | 52.49% | 52.29% | 51.54% | 49.90% | 50.56% | 52.54% | 51.58% | 47.26% | 45.91% | 48.39% | 56.80% | 56.21% | 56.04% | 55.53% | 55.52% | 60.28% | 60.40% | 62.08% | 58.95% | 55.50% | 100.00% |
| Research & Development | 54.44M | 50.13M | 46.80M | 32.86M | 30.88M | 35.71M | 39.23M | 37.56M | 45.57M | 54.19M | 54.20M | 48.64M | 36.80M | 32.66M | 26.38M | 23.86M | 24.32M | 23.88M | 26.52M | 19.99M | 17.79M | 19.51M | 19.51M | 19.04M | 14.93M | 15.10M | 17.90M | 19.00M | 18.50M | 16.70M | 15.80M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 424.68M | 369.48M | 335.16M | 271.49M | 295.38M | 293.78M | 313.42M | 299.23M | 320.07M | 335.19M | 363.24M | 314.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 7.10M | 7.20M | 4.40M | 2.70M | 4.30M | 4.50M | 3.10M | 2.50M | 3.90M | 4.50M | 3.60M | 4.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 431.78M | 376.68M | 339.56M | 274.19M | 299.68M | 298.28M | 316.52M | 301.73M | 323.97M | 339.69M | 366.84M | 318.81M | 245.26M | 213.90M | 214.48M | 198.74M | 163.12M | 137.07M | 121.35M | 118.04M | 108.45M | 97.71M | 88.87M | 86.73M | 82.76M | 86.70M | 86.90M | 92.30M | 81.80M | 75.70M | 75.90M | 77.20M | 61.00M | 0.00 |
| Other Expenses | 40.45M | 32.26M | 47.41M | 32.83M | 50.60M | 0.00 | 0.00 | -8.10M | 87.67M | 5.44M | 1.71M | -6.54M | 0.00 | -1.89M | 13.34M | 0.00 | 0.00 | -5.48M | -26.35M | -100.00K | 0.00 | 0.00 | 0.00 | 4.61M | 24.91M | 24.60M | 22.90M | 12.30M | 13.10M | 13.70M | 10.70M | 8.50M | 7.00M | 0.00 |
| Operating Expenses | 526.67M | 459.06M | 433.78M | 339.88M | 330.56M | 333.99M | 355.75M | 339.28M | 369.54M | 393.88M | 421.04M | 367.45M | 282.06M | 244.66M | 240.86M | 222.60M | 187.44M | 155.48M | 121.52M | 137.93M | 126.24M | 117.22M | 108.39M | 110.39M | 122.59M | 126.40M | 127.70M | 123.60M | 113.40M | 106.10M | 102.40M | 85.70M | 68.00M | 0.00 |
| Cost & Expenses | 1.14B | 459.06M | 921.47M | 812.50M | 834.53M | 884.03M | 847.77M | 846.90M | 873.34M | 869.83M | 891.18M | 831.31M | 640.67M | 566.15M | 548.81M | 512.31M | 446.15M | 377.79M | 320.72M | 323.66M | 318.35M | 299.48M | 273.52M | 237.34M | 244.29M | 250.40M | 254.80M | 261.40M | 223.90M | 210.00M | 196.60M | 174.50M | 146.50M | 0.00 |
| Interest Income | 0.00 | 13.00M | 5.80M | 9.40M | 13.50M | 9.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 384.00K | 399.00K | 1.97M | 0.00 | 7.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.02M | 14.63M | 17.12M | 16.83M | 16.20M | 9.91M | 4.53M | 8.10M | 9.47M | 9.38M | 10.93M | 6.54M | 0.00 | 6.00K | 742.00K | 64.00K | 0.00 | 97.00K | 0.00 | 0.00 | 0.00 | 0.00 | 13.58M | 59.39M | 13.10M | 0.00 | 74.90M | 0.00 | 0.00 | 0.00 | 0.00 | 1.60M | 1.60M | 0.00 |
| Depreciation & Amortization | 97.22M | 93.31M | 97.75M | 84.29M | 110.29M | 109.42M | 89.25M | 89.73M | 89.91M | 86.05M | 81.74M | 65.48M | 49.97M | 48.15M | 43.24M | 36.46M | 31.20M | 27.50M | 25.15M | 27.58M | 30.15M | 28.43M | 25.62M | 24.50M | 24.91M | 24.60M | 22.90M | 12.30M | 13.10M | 13.70M | 10.70M | 8.50M | 7.00M | 0.00 |
| EBITDA | 265.58M | 249.34M | 178.50M | 142.25M | 264.24M | 192.96M | 153.03M | 70.35M | 45.97M | 125.72M | 127.04M | 124.58M | 139.46M | 158.23M | 125.25M | 121.53M | 101.48M | 101.10M | 124.17M | 87.52M | 77.44M | 65.91M | 72.06M | 81.02M | 73.13M | 51.20M | 53.90M | 72.00M | 67.40M | 66.10M | 62.50M | 50.30M | 36.90M | 157.30M |
| EBITDA Ratio | 20.29% | 21.34% | 17.06% | 16.34% | 26.73% | 19.94% | 16.09% | 14.55% | 13.89% | 4.45% | 5.04% | 6.80% | 11.66% | 23.51% | 15.03% | 20.74% | 19.27% | 22.23% | 22.63% | 22.78% | 20.60% | 18.85% | 25.00% | 34.44% | 23.56% | 18.15% | 26.91% | 18.30% | 23.08% | 24.43% | 24.07% | 23.16% | 20.58% | 100.00% |
| Operating Income | 164.88M | 156.03M | 80.75M | 57.96M | 153.95M | 83.55M | 56.16M | -19.38M | -43.98M | 40.54M | 47.33M | 56.44M | 88.76M | 110.55M | 83.28M | 85.57M | 70.29M | 62.75M | 99.02M | 59.94M | 45.88M | 37.48M | 36.45M | 13.42M | 33.63M | 31.70M | 31.00M | 48.40M | 54.30M | 52.40M | 51.80M | 41.80M | 29.90M | 157.30M |
| Operating Income Ratio | 12.60% | 13.35% | 8.13% | 6.66% | 15.57% | 8.63% | 6.21% | -2.19% | -4.84% | 4.45% | 5.04% | 6.33% | 12.19% | 16.34% | 12.90% | 14.31% | 13.61% | 13.96% | 23.59% | 15.63% | 12.60% | 11.12% | 11.39% | 4.57% | 12.10% | 11.24% | 10.85% | 15.62% | 19.52% | 19.97% | 20.85% | 19.33% | 16.95% | 100.00% |
| Total Other Income/Expenses | -13.02M | -14.63M | -17.12M | 14.95M | -16.20M | -9.91M | 3.48M | -8.10M | -97.14M | -9.38M | -10.93M | -6.54M | 740.00K | -467.00K | -2.01M | -565.00K | 7.02M | 9.59M | 7.86M | -102.00K | -65.00K | 1.13M | 2.06M | 3.91M | 3.25M | 969.00K | -26.50M | 2.30M | 900.00K | 100.00K | -1.00M | -1.80M | -2.20M | -157.30M |
| Income Before Tax | 151.87M | 141.40M | 63.63M | 72.91M | 87.15M | 73.63M | 59.63M | -27.48M | -53.46M | 31.17M | 36.40M | 49.90M | 89.50M | 110.08M | 81.27M | 85.00M | 77.30M | 72.34M | 106.88M | 59.84M | 45.81M | 38.61M | 38.51M | 17.33M | 27.33M | 32.60M | 4.50M | 50.70M | 55.20M | 52.50M | 50.80M | 40.00M | 27.70M | 0.00 |
| Income Before Tax Ratio | 11.60% | 12.10% | 6.41% | 8.38% | 8.82% | 7.61% | 6.60% | -3.10% | -5.88% | 3.42% | 3.88% | 5.59% | 12.30% | 16.27% | 12.59% | 14.22% | 14.97% | 16.09% | 25.46% | 15.60% | 12.58% | 11.46% | 12.03% | 5.90% | 9.83% | 11.56% | 1.57% | 16.37% | 19.84% | 20.01% | 20.45% | 18.49% | 15.70% | 0.00% |
| Income Tax Expense | 34.31M | 26.00M | 20.25M | -6.56M | 10.63M | 18.61M | 14.06M | -1.21M | 2.16M | 14.27M | 1.25M | 11.10M | 22.61M | 30.10M | 22.90M | 25.70M | 25.32M | 23.23M | 37.81M | 20.20M | 16.49M | 10.23M | 10.78M | 10.09M | 8.47M | 11.40M | 3.90M | 17.70M | 19.30M | 18.90M | 19.30M | 15.20M | 9.70M | 0.00 |
| Net Income | 117.56M | 115.40M | 43.38M | 79.47M | 76.53M | 55.02M | 45.57M | -26.27M | -55.62M | 16.90M | 35.15M | 38.80M | 66.89M | 79.98M | 58.38M | 59.30M | 51.98M | 49.11M | 69.08M | 39.64M | 29.32M | 28.38M | 30.03M | 7.24M | 19.00M | 21.10M | -24.80M | 33.00M | 35.90M | 33.60M | 31.50M | 24.80M | 18.00M | 0.00 |
| Net Income Ratio | 8.98% | 9.87% | 4.37% | 9.13% | 7.74% | 5.69% | 5.04% | -2.96% | -6.11% | 1.86% | 3.75% | 4.35% | 9.19% | 11.82% | 9.04% | 9.92% | 10.07% | 10.92% | 16.46% | 10.33% | 8.05% | 8.42% | 9.38% | 2.46% | 6.84% | 7.48% | -8.68% | 10.65% | 12.90% | 12.80% | 12.68% | 11.47% | 10.20% | 0.00% |
| EPS | 2.32 | 2.27 | 0.85 | 1.57 | 1.51 | 1.07 | 0.86 | -0.51 | -1.09 | 0.33 | 0.68 | 0.76 | 1.30 | 1.59 | 1.15 | 1.17 | 1.00 | 0.92 | 1.29 | 0.77 | 0.60 | 0.57 | 0.57 | 0.14 | 0.30 | 0.39 | -0.47 | 0.61 | 0.66 | 0.61 | 0.56 | 0.45 | 0.33 | 0.26 |
| EPS Diluted | 2.29 | 2.24 | 0.84 | 1.55 | 1.48 | 1.04 | 0.85 | -0.51 | -1.09 | 0.32 | 0.67 | 0.74 | 1.30 | 1.56 | 1.12 | 1.14 | 0.97 | 0.89 | 1.25 | 0.75 | 0.60 | 0.56 | 0.56 | 0.14 | 0.29 | 0.39 | -0.47 | 0.60 | 0.65 | 0.59 | 0.55 | 0.44 | 0.32 | 0.25 |
| Weighted Avg Shares Out | 50.71M | 50.78M | 51.05M | 50.69M | 50.69M | 51.53M | 52.76M | 51.51M | 50.91M | 51.53M | 51.61M | 51.35M | 50.73M | 50.15M | 50.90M | 50.78M | 51.65M | 53.49M | 52.96M | 51.05M | 48.87M | 49.18M | 52.43M | 50.60M | 52.17M | 53.49M | 52.77M | 54.38M | 54.39M | 55.54M | 55.75M | 55.73M | 55.38M | 55.60M |
| Weighted Avg Shares Out (Dil) | 51.40M | 51.42M | 51.35M | 51.29M | 51.82M | 52.94M | 53.50M | 51.52M | 50.91M | 52.09M | 52.38M | 52.26M | 51.59M | 51.19M | 52.13M | 52.35M | 53.49M | 55.30M | 54.95M | 52.85M | 49.28M | 50.10M | 54.31M | 52.01M | 53.00M | 53.77M | 53.33M | 54.83M | 55.23M | 56.95M | 57.80M | 57.01M | 57.14M | 55.60M |
Robust Plasma Sales, New Innovations Aid Haemonetics Stock
HAE's hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the initiation of HAELO, a global, pivotal Phase 3 study of NTLA-2002 for...
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2025 Results: November 7, 2024
BOSTON , Oct. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, November 7, 2024. The Company will hold a conference...
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
ZUG, Switzerland, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of six abstracts, two for oral...
HAE vs. BSX: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?
Here's Why You Should Add HAE Stock in Your Portfolio Now
Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics.
4 Medical Product Stocks to Buy From a Prospective Industry
Ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, BAX, HAE and PAHC are well-poised to gain from the favorable factors.
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that data from the Phase 2 study of NTLA-2002 will be presented at...
HAE or BSX: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Products stocks have likely encountered both Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024
ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, is highlighting the differentiated profile of deucrictibant as a prophylactic...
Source: https://incomestatements.info
Category: Stock Reports